Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two Patents, Seven Applications Related to RNAi

Premium
Title: RNA Interference-Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid
 
Number: 7,176,304
 
Filed: May 11, 2004
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention “concerns methods and reagents useful in modulating vascular endothelial growth factor … and/or vascular endothelial growth factor receptor … gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications,” according to the patent’s abstract. “Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity,” the abstract states.
 

 
Title: Modulation of STAT5 Expression
 
Number: 7,176,303 
 
Filed: Nov. 6, 2003
 
Lead Inventor: Susan Freier, Isis Pharmaceuticals
 
The patent, its abstract states, covers “compounds, compositions, and methods … for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5 [and] methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5.”
 

 
Title: ES Cells Having Enhanced RNAi Effect
 
Number: 20070033663
 
Filed: Oct. 5, 2006
 
Lead Inventor: Motoya Katsuki, Mitsubishi Chemical
 
“The object of the … invention is to provide ES cells and mammals having enhanced RNAi effect, which can be used to analyze gene functions at an individual level,” the patent application’s abstract states. The invention “provides ES cells having enhanced RNAi effect, which are obtained by performing genetic manipulation on ES cells.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20070032441
 
Filed: May 24, 2004 PCT Filed: May 24, 2004
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, cosmetic, cosmeceutical, prophylactic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease (e.g., cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases), condition, trait (e.g., hair growth and removal), genotype or phenotype that responds to modulation of gene expression or activity in a cell, tissue, or organism. Such small nucleic acid molecules can be administered systemically, locally, or topically,” the abstract adds.
 

 
Title: Oligonucleotides Directed Against a Survivin Gene and Use Thereof
 
Number: 20070032440
 
Filed: Feb. 9, 2004 PCT Filed: Feb. 9, 2004
 
Lead Inventor: Axel Meye, Technische Universitat Dresden
 
The invention “relates to oligonucleotides directed against a survivin gene and variants thereof and to the use of said oligonucleotides in the diagnosis, prophylaxis, reduction and follow-up of diseases associated with cell growth, differentiation and/or division, such as tumor diseases,” the patent application’s abstract states.
 

 
Title: Functional and Hyperfunctional siRNA
 
Number: 20070031844
 
Filed: Nov. 14, 2003
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”
 

 
Title: Bioinformatically Detectable Group of Novel Regulatory Bacterial and Bacterial-Associated OIigonucleotides and Uses Thereof
 
Number: 20070031843
 
Filed: May 24, 2004
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
The invention “relates to a first group of novel bacterial and human associated oligonucleotides, here identified as ‘Genomic Address Messenger’ or ‘GAM’ oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as ‘Genomic Record’ or ‘GR’ polynucleotide,” the patent application’s abstract states. “GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various bacterial infections. Nucleic acid molecules are provided respectively encoding 21,916 bacterial and 6,100 human GAM precursor oligonucleotides, and 6,056 bacterial and 430 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”
 

 
Title: Bioinformatically Detectable Group of Novel Vaccinia Regulatory Genes and Uses Thereof 
 
Number: 20070031823
 
Filed: Aug. 28, 2003
 
Inventor: Isaac Bentwich, Rosetta Genomics
 
The invention “relates to a group of novel viral RNA regulatory genes, here identified as ‘viral genomic address messenger genes’ or ‘VGAM genes’, and as ‘genomic record’ or ‘GR’ genes,” according to the patent application’s abstract. “VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease,” the abstract states. “Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.”
 

 
Title: Dicer-Interacting Proteins and Uses Therefore 
 
Number: 20070031417
 
Filed: April 14, 2005
 
Inventor: Craig Mello, University of Massachusetts
 
The patent application, its abstract states, covers “Dicer (e.g., DCR-1) interactors … [and] methods to positively or negatively modulate Dicer activity. Uses of Dicer interactors as drug targets are featured [in the invention]. Also featured are uses of Dicer interactors and modulators of same to modulate various Dicer functions in vitro, in cell cultures, and in vivo.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.